Chinese biopharma specialist Hanbon navigates IPO journey amid patent conflicts with Cytiva
In what is a pivotal moment for it, a Chinese chromatography-instruments company that is seeking an initial public offering is striving to dispel a shadow cast by its patent disputes with...To view the full article, register now.
Already a subscriber? Click here to view full article